In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts

Cancer Immunity

Volumn 3, Issue , 2003, Pages 1-7

  Donda, Alena ^a   Cesson, Valérie ^a   Mach, Jean Pierre ^a   Corradin, Giampietro ^a   Primus, F James ^b   Robert, Bruno ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIV MONTPELLIER   (France)

Author keywords

Fab immunoglobulins; Immunoconjugates; Immunotherapy; Mice; Tumor antibodies

Indexed keywords

ANTIBODY CONJUGATE; CARCINOEMBRYONIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN F(AB) FRAGMENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 H 2KB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 35A7; OVALBUMIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOMA; CELL SPECIFICITY; CELL TRANSFER; COLON CARCINOMA; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXIC T LYMPHOCYTE; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; ISOGRAFT; ISOTOPE LABELING; MOUSE; NONHUMAN; SPLEEN CELL; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR REGRESSION;

EID: 3042743864     PISSN: 14249634     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33. (PMID: 9704735)
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48. (PMID: 10561337)
3. Delaloye B, Bischof-Delaloye A, Buchegger F, von Fliedner V, Grob JP, Volant JC, Pettavel J, Mach JP. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1986; 77: 301-11. (PMID: 3484753)
4. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12: 1561-71. (PMID: 8040668)
5. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 337-65. (PMID: 8011285)
6. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-8. (PMID: 9050879)
7. Old LJ. Cancer/testis (CT) antigens - a new link between gametogenesis and cancer. Cancer Immun 2001; 1: 1. (PMID: 12747762)
8. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80: 219-30. (PMID: 9935203)
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7. (PMID: 9500606)
10. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85. (PMID: 10371507)
11. Parmiani G, Sensi M, Castelli C, Rivoltini L, Anichini A. T-cell response to unique and shared antigens and vaccination of cancer patients. Cancer Immun 2002; 2: 6. (PMID: 12747751)
12. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-94. (PMID: 7576053)
13. Ogg GS, Dunbar PR, Cerundolo V, McMichael AJ, Lemoine NR, Savage P. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br J Cancer 2000; 82: 1058-62. (PMID: 10737389)
14. Robert B, Guillaume P, Luescher I, Romero P, Mach JP. Antibody-conjugated MHC class I tetramers can target tumor cells for specific lysis by T lymphocytes. Eur J Immunol 2000; 30: 3165-70. (PMID: 11093131)
15. Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P, Mach JP. Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments. Cancer Immun 2001; 1: 2. (PMID: 12747763)
16. Savage P, Cowburn P, Clayton A, Man S, Lawson T, Ogg G, Lemoine N, McMichael A, Epenetos A. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice. Int J Cancer 2002; 98: 561-6. (PMID: 11920616)
17. Lev A, Novak H, Segal D, Reiter Y. Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes. J Immunol 2002; 169: 2988-96. (PMID: 12218113)
18. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76: 17-27. (PMID: 8287475)
19. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998; 58: 1469-77. (PMID: 9537250)
20. Kalergis AM, Goyarts EC, Palmieri E, Honda S, Zhang W, Nathenson SG. A simplified procedure for the preparation of MHC/peptide tetramers: chemical biotinylation of an unpaired cysteine engineered at the C-terminus of MHC-I. J Immunol Methods 2000; 234: 61-70. (PMID: 10669770)
21. Buchegger F, Haskell CM, Schreyer M, Scazziga BR, Randin S, Carrel S, Mach JP. Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice. J Exp Med 1983; 158: 413-27. (PMID: 6886623)
22. Robert B, Mach JP, Mani JC, Ychou M, Folli S, Artus JC, Pelegrin A. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha. Cancer Res 1996; 56: 4758-65. (PMID: 8840995)
23. Kennedy NJ, Russell JQ, Michail N, Budd RC. Liver damage by infiltrating CD8+ T cells is Fas dependent. J Immunol 2001; 167: 6654-62. (PMID: 11714837)
24. Attinger A, MacDonald HR, Acha-Orbea H. Lymphoid environment limits superantigen and antigen-induced T cell proliferation at high precursor frequency. Eur J Immunol 2001; 31: 884-93. (PMID: 11241294)
25. Xu X, Clarke P, Szalai G, Shively JE, Williams LE, Shyr Y, Shi E, Primus FJ. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res 2000; 60: 4475-84. (PMID: 10969795)
26. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by T cells. Nature 1985; 314: 628-31. (PMID: 2859527)
27. Perez P, Hoffman RW, Shaw S, Bluestone JA, Segal DM. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature 1985; 316: 354-6. (PMID: 3160953)
28. Ferrini S, Prigione I, Miotti S, Ciccone E, Cantoni C, Chen Q, Colnaghi MI, Moretta L. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones. Int J Cancer 1991; 48: 227-33. (PMID: 1826900)
29. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F, Rivoltini L, Colnaghi MI. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992; Suppl 7: 78-81. (PMID: 1428412)
30. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264: 833-5. (PMID: 8171337)
31. Grosse-Hovest L, Brandl M, Dohlsten M, Kalland T, Wilmanns W, Jung G. Tumor-growth inhibition with bispecific antibody fragments in a syngeneic mouse melanoma model: the role of targeted T-cell co-stimulation via CD28. Int J Cancer 1999; 80: 138-44. (PMID: 9935244)
32. Dohlsten M, Hedlund G, Akerblom E, Lando PA, Kalland T. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci USA 1991; 88: 9287-91. (PMID: 1924393)
33. Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Sogaard M, Dohlsten M. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA. Int J Cancer 1999; 81: 156-63. (PMID: 1924393)
34. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 2000; 13: 265-76. (PMID: 10981969)
35. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21: 403-10. (PMID: 10916144)
36. Mach JP. Tumours: Targeting of monoclonal antibodies for imaging and potential for therapy. In: Encyclopedia of Life Sciences. London: Nature Publishing Group; 2002. p. 1-13. URL: http://www.els.net
37. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-68. (PMID: 11900991)
38. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab′ gamma)2 antibody containing thioether-linked Fab′ gamma fragments. J Immunol 1987; 139: 2367-75. (PMID: 2958547)